Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 1, 2026 to Dec 2026v4
  2. Start date: Apr 30, 2026 to Jul 1, 2026v3
  3. Secondary endpoints: details revised at 3 of 6 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Trial Details
NCT Number NCT07527325
Lead Sponsor University of California, Irvine
Collaborators: UC Cancer Consortium
Conditions Melanoma (Skin)
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov